论文部分内容阅读
氨氯地平(amlodipine besylate)为双氢吡啶钙拮抗剂,已由美国FDA批准经口服每日1次治疗高血压、慢性持续性心绞痛及血管痉挛(变异型)性心绞痛。药动学氨氯地平从胃肠道缓慢吸收;1次口服后6～12小时可达血药峰值,并可达到1周的稳定状态。此药在肝内代谢,并随尿排出,其半减期为30～50小时。老年患者代谢较慢,血药峰值较高。临床评价对慢性持续性心绞痛患者所作的双盲试验发现,氨氯地平较安慰剂有效,在减少心绞痛发作次数和增加运动时间方面与地尔硫(艹卓)或β-阻滞剂纳多洛尔(nadolol)一样有效。134例慢性持续心绞痛患者在单
Amlodipine besylate is a dihydropyridine calcium antagonist and has been approved by the U.S. FDA for the treatment of hypertension, chronic persistent angina, and vasospastic (variant) angina once daily. Pharmacokinetics amlodipine slowly absorbed from the gastrointestinal tract; 1 oral 6 to 12 hours after up to peak blood levels, and can reach 1 week steady state. The drug metabolism in the liver, and with the urine, the half-period of 30 to 50 hours. Elderly patients with slower metabolism, high blood peak. Clinical evaluation of patients with chronic persistent angina double-blind trial found that amlodipine more effective than placebo in reducing the frequency of angina attacks and increase exercise time and diltiazem (艹 Zhuo) or β-blockers Nadollo Like nadolol. 134 patients with chronic persistent angina in the single